Nath Bio-Genes (India) Limited (NSE: NATHBIOGEN)
India
· Delayed Price · Currency is INR 184.88
-3.63 (-1.93%)
Dec 24, 2024, 3:29 PM IST
Nath Bio-Genes (India) Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Operating Revenue | 3,508 | 3,326 | 3,014 | 2,784 | 3,076 | 2,799 | Upgrade
|
| Other Revenue | 1.41 | 1.41 | - | - | -0 | - | Upgrade
|
| Revenue | 3,510 | 3,328 | 3,014 | 2,784 | 3,076 | 2,799 | Upgrade
|
| Revenue Growth (YoY) | 6.96% | 10.42% | 8.26% | -9.49% | 9.89% | 21.20% | Upgrade
|
| Cost of Revenue | 923.16 | 839.27 | 814.33 | 936.65 | 980.14 | 944.2 | Upgrade
|
| Gross Profit | 2,587 | 2,488 | 2,199 | 1,847 | 2,095 | 1,855 | Upgrade
|
| Selling, General & Admin | 535.28 | 442.1 | 372.48 | 382.11 | 410.98 | 354.31 | Upgrade
|
| Other Operating Expenses | 1,556 | 1,546 | 1,338 | 1,088 | 1,013 | 952.22 | Upgrade
|
| Operating Expenses | 2,125 | 2,021 | 1,741 | 1,501 | 1,452 | 1,321 | Upgrade
|
| Operating Income | 461.77 | 467.47 | 458.79 | 345.7 | 643.36 | 533.65 | Upgrade
|
| Interest Expense | -86.46 | -86.29 | -95.73 | -101.25 | -79.02 | -63.37 | Upgrade
|
| Interest & Investment Income | 3.23 | 3.23 | 0.18 | 10.93 | 12.14 | 13.02 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | 4.3 | 0.59 | -1.23 | 2.28 | Upgrade
|
| Other Non Operating Income (Expenses) | -2.98 | -3.26 | -5.93 | -3.88 | -8.45 | -1.67 | Upgrade
|
| EBT Excluding Unusual Items | 375.55 | 381.15 | 361.59 | 252.08 | 566.79 | 483.91 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.01 | 0.01 | -0.01 | 0.04 | 0.04 | 0.27 | Upgrade
|
| Other Unusual Items | 34.49 | 34.49 | - | -887.82 | - | - | Upgrade
|
| Pretax Income | 410.05 | 415.65 | 361.64 | -634.34 | 567.51 | 485.08 | Upgrade
|
| Income Tax Expense | 15.99 | 19.46 | 11.53 | 39.52 | 10.9 | -19.76 | Upgrade
|
| Net Income | 393.73 | 396.19 | 350.11 | -673.85 | 556.62 | 504.84 | Upgrade
|
| Net Income to Common | 393.73 | 396.19 | 350.11 | -673.85 | 556.62 | 504.84 | Upgrade
|
| Net Income Growth | 3.91% | 13.16% | - | - | 10.26% | 31.35% | Upgrade
|
| Shares Outstanding (Basic) | 19 | 19 | 19 | 19 | 19 | 19 | Upgrade
|
| Shares Outstanding (Diluted) | 19 | 19 | 19 | 19 | 19 | 19 | Upgrade
|
| Shares Change (YoY) | -0.20% | - | - | - | - | - | Upgrade
|
| EPS (Basic) | 20.64 | 20.85 | 18.42 | -35.46 | 29.29 | 26.56 | Upgrade
|
| EPS (Diluted) | 20.64 | 20.85 | 18.42 | -35.46 | 29.29 | 26.56 | Upgrade
|
| EPS Growth | 4.12% | 13.16% | - | - | 10.26% | 31.35% | Upgrade
|
| Free Cash Flow | -182.63 | 478.18 | 354.85 | -39.56 | -104.34 | 52.42 | Upgrade
|
| Free Cash Flow Per Share | -9.58 | 25.16 | 18.67 | -2.08 | -5.49 | 2.76 | Upgrade
|
| Dividend Per Share | 2.000 | 2.000 | 2.000 | 2.000 | 2.000 | - | Upgrade
|
| Gross Margin | 73.70% | 74.78% | 72.98% | 66.35% | 68.13% | 66.27% | Upgrade
|
| Operating Margin | 13.16% | 14.05% | 15.22% | 12.42% | 20.92% | 19.07% | Upgrade
|
| Profit Margin | 11.22% | 11.91% | 11.62% | -24.21% | 18.10% | 18.04% | Upgrade
|
| Free Cash Flow Margin | -5.20% | 14.37% | 11.77% | -1.42% | -3.39% | 1.87% | Upgrade
|
| EBITDA | 495.59 | 499.99 | 488.91 | 376.54 | 671.52 | 548.18 | Upgrade
|
| EBITDA Margin | 14.12% | 15.03% | 16.22% | 13.53% | 21.83% | 19.59% | Upgrade
|
| D&A For EBITDA | 33.82 | 32.52 | 30.12 | 30.84 | 28.16 | 14.53 | Upgrade
|
| EBIT | 461.77 | 467.47 | 458.79 | 345.7 | 643.36 | 533.65 | Upgrade
|
| EBIT Margin | 13.16% | 14.05% | 15.22% | 12.42% | 20.92% | 19.07% | Upgrade
|
| Effective Tax Rate | 3.90% | 4.68% | 3.19% | - | 1.92% | - | Upgrade
|
| Revenue as Reported | 3,515 | 3,333 | 3,019 | 2,802 | 3,092 | 2,817 | Upgrade
|
| Advertising Expenses | - | 50.51 | 37.04 | 16.34 | 19.43 | 26.11 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.